Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

AAM, AHIP, FTC: FDA Should Retract Plan For Suffixes In Biologic Naming

By Beth Wang
May 8, 2019 at 5:44 PM
The government and major lobby groups oppose FDA’s biologic naming convention, which says that all new biologics, biosimilars and interchangeable biosimilars must have a nonproprietary name followed by a non-meaningful suffix. While the groups agree all products should share a common nonproprietary name, they argue against the use of suffixes of any kind. They also argue that FDA’s proposal to not apply the naming convention to already-approved products is a major misstep that will cause confusion among patients and health...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.